Condition: Sever Aplastic Anaemia · Elderly (People Aged 65 or More) · Immunosuppressive Treatment · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA/SAA.
This description comes directly from the study's public registry record.
Jianping Li, MD · +8613820961539 · lijianping@ihcams.ac.cn
Jingyu Zhao, MPH · +8613752253515 · zhaojingyu@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Red Blood Cell Diseases Center | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07010237